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Nitric oxide (NO) plays a critical role in the motoric and glutamate releasing action of
N-methyl-D-aspartate (NMDA)-antagonist stimulants. Earlier studies utilized neuronal
nitric oxide synthase inhibitors (nNOS) for studying the neurobehavioral effects
of non-competitive NMDA-antagonist stimulants such as dizocilpine (MK-801) and
phencyclidine (PCP). This study explores the role of the inducible nitric oxide synthase
inhibitors (iNOS) aminoguanidine (AG) and (-)-epigallocatechin-3-gallate (EGCG) in
NMDA-antagonist induced motoric behavior and prefrontal cortical glutamate efflux.
Adult male rats were administered a dose range of AG, EGCG, or vehicle prior
to receiving NMDA antagonists MK-801, PCP, or a conventional psychostimulant
(cocaine) and tested for motoric behavior in an open arena. Glutamate in the
medial prefrontal cortex (mPFC) was measured using in vivo microdialysis after a
combination of AG or EGCG prior to MK-801. Acute administration of AG or EGCG
dose-dependently attenuated the locomotor and ataxic properties of MK-801 and
PCP. Both AG and EGCG were unable to block the motoric effects of cocaine,
indicating the acute pharmacologic action of AG and EGCG is specific to NMDA
antagonism and not generalizable to all stimulant class drugs. AG and EGCG normalized
MK-801-stimulated mPFC glutamate efflux. These data demonstrate that AG and
EGCG attenuates NMDA antagonist-stimulated motoric behavior and cortical glutamate
efflux. Our results suggest that EGCG-like polyphenol nutraceuticals (contained in
“green tea” and chocolate) may be clinically useful in protecting against the adverse
behavioral dissociative and cortical glutamate stimulating effects of NMDA antagonists.
Medications that interfere with NMDA antagonists such as MK-801 and PCP have been
proposed as treatments for schizophrenia.
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INTRODUCTION
One important second messenger system involved in signal
transduction for many neurotransmitters, including glutamate,
is nitric oxide (NO; Garthwaite, 1991). Several groups have
evaluated whether nitric oxide synthase (NOS) inhibition
counteracts the behavioral eﬀects of psychotomimetic N-methyl-
D-aspartate (NMDA) subtype of glutamate receptor antagonists
(Wiley, 1998; Bujas-Bobanovic et al., 2000). Studies using either
non-speciﬁc or neuronal nitric oxide synthase (nNOS) inhibitors
yielded conﬂicting results. Some studies showed that nNOS
inhibitors, like glycine-type NMDA agonists, block the behavioral
eﬀects of phencyclidine (PCP)-like NMDA antagonists (Deutsch
et al., 1996; Klamer et al., 2004). While others show enhanced
responsiveness to PCP when pretreated with nNOS inhibitors
(Bujas-Bobanovic et al., 2000). Subsequent studies utilizing
nNOS gene deletion in knockout mice showed diminished
responsiveness to PCP (Bird et al., 2001). Collectively, these
studies established a causal role for nNOS in glutamate signaling.
Relative to nNOS, few studies have examined a role for
NO derived from the inducible isoform (iNOS) in glutamate
signaling. This is presumably because iNOS is not enzymatically
detectable in “naïve” animals and is mainly observed in the
context of signiﬁcant neuronal injury (Licinio et al., 1999;
Cardenas et al., 2000; Amitai, 2010). Although conﬁned to glial
cells, iNOS, if activated by the neurotoxic action of NMDA
receptor blockade would generate a readily diﬀusible gas capable
of reaching behaviorally relevant neuronal sites (Olney et al.,
1991).
Aminoguanidine (AG) has extensively been used for
preferentially inhibiting iNOS expression in the brain (Iadecola
et al., 1995; Corbett and McDaniel, 1996; Lecanu et al., 1998;
Wada et al., 1998; Olivenza et al., 2000; Sugimoto and Iadecola,
2002; Harvey et al., 2004; Louin et al., 2006; Udayabanu et al.,
2008). Another compound that inhibits iNOS expression is
(-)-epigallocatechin-3-gallate (EGCG; Chan et al., 1997; Lin and
Lin, 1997; Kim et al., 2010). EGCG is the major polyphenol
in “green tea” and considered the central bioactive molecule
responsible for the health beneﬁts of green tea (Liao et al., 2001).
Establishing a role for the iNOS inhibitors AG and EGCG in
NMDA antagonist action is of signiﬁcant clinical interest because
NMDA medications have been proposed as treatments for
schizophrenia (Neill et al., 2010).
In this series of experiments we evaluated the structurally
unrelated iNOS inhibitors aminoguanidine and EGCG for their
potential to block the potent motoric eﬀects of the NMDA
antagonist dizocilpine (MK-801) and PCP. Cocaine was included
into the experimental design as a control for evaluating the
generalizability of AG and EGCG on motoric behavior from all
stimulants, regardless of mechanism.We hypothesized that iNOS
inhibitors (AG and EGCG) attenuate the acute psychostimulant
properties of the NMDA-antagonists MK-801 and PCP at doses
that do not diminish cocaine-induced locomotion.
In addition to motoric behavior, NMDA receptor antagonists
alsomediate prefrontal glutamate release. Administration ofMK-
801 has been shown to elevate prefrontal glutamate (Moghaddam
et al., 1997; Moghaddam and Adams, 1998; Lorrain et al.,
2003) and PCP reduces prefrontal glutamate (Fattorini et al.,
2008, 2009). No study to date has directly tested whether iNOS
inhibition, as has earlier been reported for nNOS inhibition
(Roenker et al., 2012), is suﬃcient to mediate MK-801-
induced medial prefrontal cortical (mPFC) glutamate release.
We hypothesized that AG and EGCG would inhibit MK-801-
stimulated mPFC extracellular glutamate release as measured by
in vivomicrodialysis (Darvesh et al., 2011).
MATERIALS AND METHODS
Animals
Experimentally naïve male Sprague–Dawley rats (Harlan;
Indianapolis, IN, USA) were tested in all experiments. Rats
averaged 70–100 days of age, weighed between 150–250 g at time
of testing and were maintained on a 12:12 light:dark cycle (lights
on at 0600) with an ambient temperaturemaintained at 21± 2◦C.
Food and water were available ad libitum. Animal husbandry was
in accordance with the National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals (2011) and approved
by the Portland Veterans Aﬀairs Institutional Animal Care and
Use Committee (IACUC). Disclosure of housing and husbandry
procedures was in accordance with recommendations for
standard experimental reporting in behavioral neuroscience
research (Prager et al., 2011).
Drugs
Dizocilpine maleate ((+)-MK-801), phencyclidine hydrochloride
(PCP), and cocaine hydrochloride (COC) were obtained
from Research Biochemicals International (RBI; Natick, MA,
USA). (-)-Epigallocatechin gallate (EGCG) and aminoguanidine
hydrochloride (AG) were obtained from Sigma (St Louis, MO,
USA). All drugs were diluted to appropriate concentrations in
physiological saline (Abbott laboratories; North Chicago, IL,
USA). Injection volume was 0.1 ml 100g−1 body weight for all
drug-treated rats, and for vehicle.
Apparatus
Rats were tested in automated locomotor activity monitors
(Accuscan Instruments Inc. Columbus, OH, USA). Each
test chamber comprised a clear acrylic plastic box (43 cm
wide x 43 cm long x 20 cm tall; 17 x 17 x 8) with a clear plastic
lid (47 cm x 47 cm) perforated for ventilation. Each box was
placed inside a 43 cm x 43 cm square monitor, with 15 photocell
beams equally spaced (1′′ on center) on each axis at right angles
to one another, 2 cm above the ﬂoor. Each monitor and box sat
inside a sound-dampening, light-proof cabinet. The inside was
illuminated by a 25-watt halogen light during testing. Internal
fans provided ventilation and a ﬁxed level of background noise.
Schedule and Procedure
Experiment 1: AG and NMDA-antagonist-induced
motoric Behavior
On test day, rats were transferred in the home cage to the testing
room and allowed to habituate for 45–60 min Rats received
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intraperitoneal (i.p.) injections of AG (40, 100, 400 mg/kg)
or saline (vehicle) and placed into the activity chambers for
30 min. The dose range for i.p. administration of AG was
based on several previous reports (Olivenza et al., 2000; Louin
et al., 2006). The initial 30 min period allowed for habituation
to the novel environment. Upon completion of the 30 min
interval, the animals were removed from the chambers, placed in
their home cages and, depending on group assignment, injected
with MK-801 (MK; 0.25 mg/kg), PCP (20 mg/kg), cocaine
(COC, 30 mg/kg), or an equal volume of saline vehicle (SAL).
Immediately following injection, rats were transferred back into
their original testing chambers for a 60 min test session. Previous
studies suggest a 60 min window provides ample time for the
full expression of the locomotor stimulant eﬀects of MK-801,
PCP, and COC (Diana and Sagratella, 1994; Hargreaves and
Cain, 1995). Data were collected in 1-min time periods and
quantiﬁed in 5-min bins. DRUG 1 (iNOS inhibitor or vehicle)
was followed 30 min later by DRUG 2 (NMDA antagonist,
cocaine, or vehicle), resulting in the following groups: iNOS
inhibitor/NMDA antagonist, vehicle/NMDA antagonist, iNOS
inhibitor/vehicle, vehicle/vehicle.
Experiment 2: AG and NMDA Antagonist-induced
Ataxia and Stereotypy
A possible explanation for any eﬀects of AG on NMDA-
antagonist-induced locomotor behavior is that iNOS inhibitors
shift the behavioral dose response curve leftward, increasing
overall responsiveness. As the dose of the stimulant increases,
motoric behaviors may decrease due to an increase in competing
stereotypic or ataxic behaviors. Therefore, a reduction in
locomotor activity due to iNOS inhibition could have been due
to an increase in stereotypic and/or ataxic behavior. To test this
possibility, ataxic and stereotypic behaviors in a separate group
of rats was measured in the novel open ﬁeld (same apparatus
as above experiments) using a dosing schedule identical to that
used for the locomotor experiments. Rats were administered
SAL or AG (100 mg/kg) and placed into the activity chamber
for 30 min. Then, rats were administered either SAL or MK,
and placed into the chambers for 60 min. Rats were rated for
ataxic and stereotypic behaviors using a well-validated rating
scale adapted from (Sturgeon et al., 1979) (see Supplemental
Material). This rating scale has been used for quantifying PCP-
induced stereotypy and ataxic behavior in rats. All ratings were
conducted by trained experimenters who scored the behavior of
each rat for each of the two scales for 15–20 s at 10 min intervals
over 60 min. Locomotor data was simultaneously collected. PCP
was not evaluated for ataxic and stereotypic behaviors because
PCP and MK-801 are both classiﬁed as non-competitive NMDA
antagonists and produce relatively similar eﬀects on motoric,
stereotypic, and ataxic behaviors (Koek et al., 1988; Hiramatsu
et al., 1989). We did not evaluate cocaine because we did not ﬁnd
eﬀects of AG on cocaine-induced locomotor activity.
Experiment 3: EGCG and NMDA Antagonist-induced
Motoric Behavior
Since iNOS is not constitutively present in the brain this raises the
question of why an iNOS inhibitor would be behaviorally active.
One possible explanation would be that AG has behavioral eﬀects
by an iNOS independent mechanism. We therefore examined
whether EGCG (10, 30, 100mg/kg), a structurally unrelated iNOS
inhibitor, had comparable behavioral eﬀects using a dosing and
behavioral protocol identical to that described above for AG. The
dose range for i.p. administration of EGCG was based on several
previous reports (Vignes et al., 2006; Ge et al., 2013). Because
AG was found to diminish stereotypic and ataxic behavior after
MK-801, stereotypy and ataxia was not characterized following
EGCG/MK-801.
Experiment 4: In Vivo Microdialysis of Cortical
Glutamate
To our knowledge, no study to date has measured MK-801-
induced mPFC extracellular glutamate release in the presence
of an iNOS inhibitor. Rats were implanted with a stainless steel
guide cannula under isoﬂurane anesthesia three days prior to
insertion of the microdialysis probe. On the day prior to the
experiment, a concentric style dialysis probe was positioned in
the mPFC. The coordinates for the probe tip were AP: +3.2 mm,
ML: +0.5 mm, DV: –5.0 mm from the bregma (Paxinos and
Watson, 1986). The length of the probe membrane was 3.0 mm.
The probe was connected to an infusion pump set to deliver
aCSF (in mM: 140 NaCl, 3.4 KCl, 1.5 CaCl2, 1.0 MgCl2, 1.4
NaH2PO4, 4.85 NaHPO4, pH 7.4). The aCSF was allowed to ﬂow
through the probe overnight at a ﬂow rate of 0.2 μl/min. On
the morning of the experiment, the ﬂow rate was increased to
2.0 μl/min and after 1 h equilibration period, dialysis samples
were collected every 15 min for 4 h. Glutamate levels were
measured by HPLC analysis (Donzanti and Yamamoto, 1988).
Based on the experiments described above showing the lowest
eﬀective dose ranges for blocking MK-801-induced locomotor
behavior, rats were injected (i.p.) with AG (100 mg/kg), EGCG
(100 mg/kg), or vehicle (saline) 30 min prior to an injection
of MK-801 (0.30 mg/kg) or vehicle. The slightly higher dose
of MK-801 used in the microdialysis experiment (0.30 mg/kg)
versus locomotor activity experiments (0.25 mg/kg) was based
on a similar previous in vivo microdialysis study of MK-801-
induced glutamate release and NO inhibition in the rat prefrontal
cortex (Roenker et al., 2012). PCP and cocaine were not included
into the experimental design as the eﬀects of iNOS inhibition on
PCP were comparable with MK-801 and iNOS was ineﬀective in
blocking cocaine-induced locomotion.
Data Analyses
For locomotor activity, the dependent variable was mean beam
breaks in the open ﬁeld. For ataxic and stereotopic behavior,
the dependent variable was the mean ataxia or stereotypy
rating on a 0–5 scale (Sturgeon et al., 1979) (see Supplemental
Materials). For the microdialysis experiments, glutamate
measures were transformed to a percent of mean baseline value
(% baseline). All group comparisons of behavior were conducted
using one-way analysis of variance (ANOVA) with DRUG
(iNOS inhibitor, stimulant, iNOS inhibitor/stimulant, saline)
deﬁned as the between-groups factor. Homogeneity of variance
was checked using Levene’s test and corrected if warranted
using the Brown–Forsythe F. Follow-up post hoc comparisons
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(Fisher’s LSD post hoc) were only performed subsequent to a
statistically signiﬁcant ANOVA test. Time course locomotor and
microdialysis glutamate measures across the testing sessions was
conducted using ANOVAwith repeated measures on the variable
TIME. Signiﬁcant interactions were followed up with post hoc
comparisons (Fisher’s LSD post hoc). Because the saline/saline
(saline) and saline/MK-801 (MK-801) groups were the only
groups common across all experiments, a smaller number
of subjects were run in each experiment (n = 3–4) and then
collapsed across experiments to reduce the overall number of
animals needed for experimentation. A p-value of at least 0.05
was considered signiﬁcance for all statistical tests. All data are
presented as mean ± SEM and sample size for each experiment
is indicated in the ﬁgure legends.
RESULTS
Aminoguanidine Blocks MK-801-induced
Locomotor Activity
One-way ANOVA revealed a signiﬁcant interaction of the iNOS
inhibitor AG and MK-801 on motoric behavior [F(5,55) = 17.
3, p < 0.001; Figure 1]. A post hoc test showed that MK-801
(0.25 mg/kg) potently facilitated locomotor activity compared to
the vehicle control (p < 0. 001) and AG by itself (p < 0.001).
AG signiﬁcantly blocked the locomotor eﬀects of MK-801 at the
100 mg/kg (p < 0.001) and 400 mg/kg (p < 0.001) dose, but not
40 mg/kg dose (Figure 1). The attenuating eﬀects of AG on MK-
801-induced locomotor activity at the 100 and 400 mg/kg dose
were statistically indistinguishable from each other (p = 0.15).
A time course analysis of AG at the 100 mg/kg dose with
DRUG as the between-subjects factor and TIME the within-
subject factor revealed a signiﬁcant interaction of DRUG x TIME
[F(33,407) = 10.3; p < 0.001; Figure 1]. Attenuation of MK-
801-induced locomotion by AG began 15 min post injection
(p < 0.05) and persisted throughout the 60 min time window
(p < 0.001; Figure 1). There were no signiﬁcant diﬀerences
detected between-groups prior to injection of MK-801. We also
found no signiﬁcant eﬀects of various concentrations of AG on
their own after vehicle injection (Figure 1). Time course analysis
of AG/MK-801 at the 40 and 400 mg/kg dose not shown. Overall,
these results suggest that the iNOS inhibitor AG is capable
of signiﬁcantly reducing NMDA-antagonist mediated motoric
behavior. These data also suggest that AG may have an eﬀect on
the enzymatic function of iNOS.
Aminoguanidine Attenuates
PCP-induced Locomotor Activity
One-way ANOVA revealed a signiﬁcant interaction of AG
and PCP on motoric behavior [F(3,38) = 51. 2, p < 0.001;
Figure 1]. PCP treatment signiﬁcantly increased locomotor
activity compared to vehicle and AG alone at the 20 mg/kg
dose (p = 0.001). AG (100 mg/kg) signiﬁcantly reduced the
locomotor eﬀects of PCP (p< 0.001). This result further supports
the conclusion that iNOS inhibition via AG attenuates NMDA-
antagonist mediated motoric behavior.
Aminoguanidine does not Alter
Cocaine-induced Locomotor Activity
Cocaine was included into the experiment to assess the speciﬁcity
of AG on the locomotor stimulant properties of NMDA receptor
blockade. Results from this experiment showed that AG was
unable to block the motoric eﬀects of cocaine (20 mg/kg;
Figure 1), indicating that iNOS inhibition is speciﬁc to NMDA-
mediated locomotor activity and not general to all stimulant
classes of drugs.
Aminoguanidine Attenuates
MK-801-induced Ataxia/Stereotypy
One-way ANOVA revealed a signiﬁcant interaction of the
iNOS inhibitor AG and MK-801 on ataxic [F(3,26) = 18.1;
p = 0.001; Figure 2] and stereotypic [F(3,26) = 62.0, p < 0.001;
Figure 2] behavior. MK-801 signiﬁcantly increased both ataxic
and stereotypic behavior compared to AG (p< 0.001) and vehicle
(p < 0.001). AG signiﬁcantly reduced the ataxic (p < 0. 01) and
stereotypic (p < 0.001) inducing eﬀects of MK-801. This result
indicates that the ability of AG to attenuate the stimulant eﬀects
of MK-801 is not a result of increases in competing (ataxic or
stereotypic) behaviors. MK-801 stimulated locomotor, ataxic and
stereotypic behavior is consistent with previous reports.
EGCG Blocks MK-801-induced
Locomotor Activity
We evaluated whether EGCG, another iNOS inhibitor
structurally unrelated to AG, possessed comparable behavioral
eﬀects on NMDA-mediated locomotor behavior (Figure 3).
Consistent with the AG studies, one-way ANOVA revealed
a signiﬁcant interaction of EGCG and MK-801 on motoric
behavior [F(5,81) = 22.2; p < 0.001; Figure 3]. EGCG treatment
prior to 0.25 mg/kg MK-801 reduced locomotor behavior
at the 100 mg/kg (p < 0.001) but not 30 (p = 0.08) or
10 mg/kg dose (Figure 3). A time course analysis with DRUG
as the between-subjects factor and TIME the within-subject
factor revealed a signiﬁcant interaction of DRUG x TIME
[F(33,649) = 18.8; p< 0.001; Figure 3]. Attenuation of MK-801-
induced locomotion by EGCG (100 mg/kg) began approximately
25 min post injection (p < 0.001) and persisted throughout the
60 min time window (Figure 3). Interestingly, EGCG by itself
signiﬁcantly reduced locomotor behavior relative to the saline
control at 5 min (p< 0.001) and 10 min (p< 0.05) post injection
(Figure 3). These data suggest that EGCG possesses comparable
inhibitory eﬀects on MK-801-induced locomotor behavior as the
structural unrelated iNOS inhibitor AG. Overall, these results
suggests that EGCG is capable of signiﬁcantly reducing NMDA
antagonist-mediated locomotor behavior.
EGCG Attenuates PCP-induced
Locomotor Activity
One-way ANOVA revealed a signiﬁcant interaction of EGCG and
PCP on motoric behavior [F(3,38) = 32.7, p < 0.001; Figure 3].
100 mg/kg EGCG signiﬁcantly decreased locomotor activity
induced by 20 mg/kg PCP (p < 0.05). These data strengthen
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FIGURE 1 | Aminoguandine (AG) attenuates the locomotor stimulant properties of MK-801 and phencyclidine (PCP). (A) Schematic depicting the
schedule of injections and locomotor testing. Rats were injected (i.p.) with either saline vehicle (SAL) or AG (40, 100, or 400 mg/kg) 30 min prior to SAL or MK-801
(MK; 0.25 mg/kg), PCP (5.0 mg/kg) or cocaine (COC; 20.0 mg/kg). (B) Time-course analysis of locomotor activity following injections of AG (100 mg/kg), MK-801 or
a combination of AG and MK-801. Attenuation of MK-801-induced locomotion by AG began rapidly, 15 min post injection, and persisted throughout the 60 min time
window. (C) The attenuating effects of AG on MK-801 induced locomotor behavior in the open field were dose-dependent with 40 mg/kg having no effect and 100
and 400 mg/kg potently attenuating MK-801 locomotion. (D) AG attenuated PCP-induced locomotion. (E) AG did not attenuate the psychomotor stimulant action of
cocaine. n = 9–20/group. ∗∗∗ indicates p < 0.001 MK/AG compared to MK group. Data points represent mean ± SEM.
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FIGURE 2 | Aminoguanidine attenuates MK-801-induced ataxic and stereotypic behavior. Time-course ataxia and stereotypy measures in the open field
following injections of AG (100 mg/kg), MK-801 (MK; 0.25 mg/kg), saline (SAL), or a combination of AG/MK-801. Rats were injected (i.p.) with either SAL or AG
(100 mg/kg) 30 min prior to SAL or MK. (A) AG in the presence of MK-801 attenuated ataxic behavior. (B) AG in the presence of MK-801 attenuated ataxic behavior.
n = 5–10/group. ∗∗∗p < 0.001 and ∗∗p < 0.01 AG/MK compared to MK group. Data points represent mean ± SEM. Ataxia and stereotypy rating scale adapted
from (Sturgeon et al., 1979; see Supplemental Material).
the assertion that EGCG lowers NMDA antagonist-mediated
locomotor activity.
EGCG does not Alter Cocaine-induced
Locomotor Activity
Like the AG experiment described above, cocaine was included
in the experiment to assess the speciﬁcity of EGCG on the
locomotor stimulant properties of NMDA-anatagonists. Results
from this experiment showed that EGCG was unable to block
the motoric eﬀects of cocaine (20 mg/kg; Figure 3). Overall,
these data show that although EGCG eﬀectively inhibited both
psychotomimetics, MK-801, and PCP, it did not inhibit the non-
NMDA psychomotor stimulant cocaine.
MK-801 Induces mPFC Glutamate Efflux
The NMDA receptor antagonist MK-801 signiﬁcantly elevated
extracellular glutamate levels in the mPFC relative to vehicle, a
ﬁnding consistent with previous work (Pietraszek et al., 2009;
Roenker et al., 2011, 2012). MK-801 increased glutamate levels
approximately 180% over baseline measures (Figure 4). This
increase is also consistent with previous work using the same
MK-801 dose (0.30 mg/kg i.p.; Roenker et al., 2012).
Aminoguanidine Normalizes
MK-801-induced mPFC Glutamate Efflux
The iNOS inhibitor AG (100 mg/kg) was injected (i.p.) 30 min
prior to MK-801 (0.30 mg/kg). A time course analysis of
extracellular glutamate levels with DRUG as the between-subjects
factor and TIME the within-subject factor revealed a signiﬁcant
interaction of DRUG x TIME [F(33,308) = 12.8; p < 0.001].
Subsequent post hoc testing revealed that AG signiﬁcantly
loweredMK-801-induced glutamate levels 75min following MK-
801 injection and this reduction persisted throughout the testing
session (180 min total; Figure 4). AG injections alone had no
signiﬁcant eﬀect on extracellular glutamate levels relative to the
vehicle condition. There were no pre-treatment eﬀects detected.
EGCG Blocks MK-801-stimulated
Glutamate Release
The iNOS inhibitor EGCG (100 mg/kg) was injected (i.p.)
30 min prior to MK-801 (0.30 mg/kg). A time course analysis of
extracellular glutamate levels with DRUG as the between-subjects
factor and TIME the within-subject factor revealed a signiﬁcant
interaction of DRUG x TIME [F(33,312) = 14.2; p < 0.05].
Subsequent post hoc testing revealed that EGCG signiﬁcantly
attenuated MK-801-induced glutamate levels 90 min following
MK-801 injection and this reduction persisted throughout the
testing session (180 min total; Figure 4). EGCG injections alone
had no signiﬁcant eﬀects on extracellular glutamate levels relative
to vehicle control. There were no pre-treatment eﬀects detected.
DISCUSSION
Consistent with our initial hypothesis, the iNOS inhibitors AG
and EGCG dose-dependently attenuated the potent acute motor
stimulatory eﬀects of the non-competitive NMDA antagonists
MK-801 and PCP at doses that did not diminish cocaine-induced
locomotion. MK-801 and PCP-induced ataxia and stereotypy
were also reduced by AG and EGCG, suggesting the psychomotor
attenuating eﬀects of AG and EGCG could not be attributed
to an increase in competing (ataxic or stereotypic) behaviors.
Also consistent with our initial hypothesis, both AG and EGCG
normalized MK-801-stimulated extracellular glutamate levels in
the mPFC. These are the ﬁrst reported preclinical ﬁndings
implicating AG and EGCG in both the motoric and glutamate
releasing action of NMDA antagonist stimulants.
Results from these experiments are comparable to the results
from studies assessing the eﬃcacy of known antipsychotics
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FIGURE 3 | (-)-Epigallocatechin-3-gallate (EGCG) attenuates the psychomotor stimulant action of MK-801 and PCP. (A) Schematic depicting the
schedule of injections and locomotor testing. Rats were injected (i.p.) with either vehicle (saline) or EGCG (10, 30, or 100 mg/kg) 30 min prior to vehicle saline (SAL)
or MK-801 (MK; 0.25 mg/kg). (B) Time-course locomotor activity following injections of EGCG (100 mg/kg), MK-801 or a combination of EGCG and MK-801. Beam
breaks due to locomotor activity are shown in 5-min epochs. Attenuation of MK-801-induced locomotion by EGCG (100 mg/kg) began rapidly, approximately 25 min
post injection, and persisted throughout the 60 min time window. There was also a small, but significant decrease in locomotor activity following EGCG alone
compared with saline control. (C) The attenuating effects of EGCG on MK-801 induced locomotor behavior were dose-dependent with the 10 and 30 mg/kg doses
having no effect but 100 mg/kg attenuating MK-801-induced locomotion. EGCG by itself was also found to significantly reduce locomotor behavior relative to vehicle
control. (D) EGCG was also able to attenuate PCP-induced locomotion. (E) EGCG was unable to attenuate the potent locomotor effect of cocaine (30 mg/kg).
n = 9–21/group. ∗∗∗p < 0.001 EGCG/MK compared to MK group and ∗p < 0.05 and ∗∗p < 0.01 EGCG compared to SAL. Data points represent mean ± SEM.
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FIGURE 4 | Aminoguanidine and EGCG normalize MK-801 stimulated glutamate efflux in the prefrontal cortex. Rats were injected (i.p.) with either AG
(100 mg/kg, i.p.), EGCG (100 mg/kg), or vehicle (saline) 30 min prior to MK-801 (0.30 mg/kg, i.p.) or vehicle. (A) Schematic depicting the stereotaxic location of the
microdialysis probe in the mPFC (PL/IL boundary). (B) Pretreatment with AG reduced MK-801 stimulated mPFC glutamate release beginning 75 min post-injection.
(C) Pretreatment with EGCG reduced MK-801 stimulated mPFC glutamate release beginning approximately 90 min post-injection. n = 6–8/group. PL, prelimbic
cortex; IL, infralimbic cortex. ∗∗∗p < 0.001 EGCG/MK or AG/MK compared to MK group. Data points represent mean ± SEM.
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on NMDA-antagonist-induced locomotor activity and cortical
glutamate eﬄux. Clozapine and haloperidol were both found
to attenuate MK-801-induced glutamate release in the mPFC
(Lopez-Gil et al., 2007). Typical and atypical antipsychotics
have also been demonstrated to attenuate the hyperlocomotor
action of MK-801. Prazosin (Mathe et al., 1996), risperidone
(Su et al., 2007), zotepine (Gattaz et al., 1994), haloperidol
(Hoﬀman, 1992), and clozapine (Hoﬀman, 1992) all have been
shown to attenuate the locomotor stimulant action of MK-801.
The present ﬁndings may have clinical implications because the
neurobehavioral action of NMDA-antagonists models several
dimensions of schizophrenia pathology and symptomology
(Javitt and Zukin, 1991; Neill et al., 2010).
Interestingly, EGCG at the 100 mg/kg (but not 10 and
30 mg/kg) dose produced a small but signiﬁcant reduction
in general locomotor activity compared with vehicle control,
suggesting EGCG by itself may reduce spontaneous motoric
behavior. To our knowledge, an interaction of acute EGCG
and spontaneous locomotor activity in rats has not been
previously shown. It seems unlikely that the attenuating eﬀects
of EGCG on NMDA-antagonist-induced locomotor stimulation
can solely be accounting for by non-speciﬁc motor eﬀects since
EGCG produced no statistically signiﬁcant eﬀects on cocaine-
induced locomotor activity. Another interesting interpretation
for locomotor attenuation following EGCG is the possibility
it reﬂects an acute anxiogenic property. This interpretation,
however, is inconsistent with other data demonstrating EGCG
induces anxiolytic responsivity on the elevated plus maze
(Vignes et al., 2006), reverses the anxiogenic action of caﬀeine
(Park et al., 2010) and reverses stress-induced decreases in
locomotor activity (Soung et al., 2015). AG has also been
shown to reverse anxiogenic and depressive behaviors following
social isolation stress (Amiri et al., 2015). Finally, local
injection of the more selective iNOS inhibitor 1400 W in
the dorsolateral periaqueductal gray attenuated the anxiogenic
action of ethanol withdrawal (Bonassoli et al., 2013). However,
these pharmacological ﬁndings are in direct conﬂict with data
generated using molecular genetic tools. INOS knock out mice
were found to exhibit anxiogenic-like behavioral responsivity
(Buskila et al., 2007), elevated stress reactivity (Abu-Ghanem
et al., 2008) and greater contextual fear memory (Lisboa
et al., 2015). Taken together, results from iNOS deletion mice
suggest any putative anxiolytic action of EGCG may be iNOS-
independent. This interpretation is supported by the present data
showing the iNOS inhibitor AG by itself produced no eﬀects on
motoric behavior.
There is also some evidence that iNOS inhibition impacts
cognition. EGCG has been shown to rescue cognitive deﬁcits
in a Down’s syndrome mouse model (De la Torre et al.,
2014), although see (Stringer et al., 2015). INOS inhibition has
been found to decrease learning and memory impairments in
spontaneous hypertension rats (Wang et al., 2014). EGCG was
also able to slow cognitive degeneration in mouse models of
Alzheimer’s disease (Rezai-Zadeh et al., 2008; Chang et al., 2015).
Finally, EGCG has been shown to improve spatial memory
(Haque et al., 2006). Together, these studies indicate some
cognitive improvement after iNOS inhibition via EGCG.
Our ﬁndings should be interpreted with caution. Many
of the agents which interact with iNOS also modulate other
inﬂammatory and non-inﬂammatory mechanisms such as the
enzyme semicarbazide-sensitive amine oxidase and hormones
such as testosterone and insulin (Kao et al., 2000). It is also
possible that the pharmacologic action of AG and EGCG on
NMDA-mediated motoric behavior and cortical glutamate eﬄux
was not speciﬁc to iNOS. EGCG has been shown to suppress
nNOS expression (Wei et al., 2011), COX-2 activity (Surh
et al., 2001; Ahmed et al., 2002), JAK/STAT1 signaling (Giunta
et al., 2006), DYRK1A expression (De la Torre et al., 2014),
spontaneous excitatory synaptic (Vignes et al., 2006) and NF-κB
activation (Surh et al., 2001). Future studies using iNOS gene
knock-out mice, more speciﬁc iNOS inhibitors such as 1400 W,
or measurements of iNOS expression following EGCG and AG
administration are warranted to deﬁnitively conclude the relative
contribution of iNOS to NMDA-mediated motoric behavior
and cortical glutamate eﬄux. Nevertheless, the present series
of experiments establish that AG and EGCG, two structurally
unrelated iNOS inhibitors, robustly reduce NMDA-antagonist
induced motoric behavior and cortical glutamate eﬄux.
iNOS Induction and Expression
In the adult brain, excess NO has been classically associated
with inﬂammation, injury or trauma. The inducible isoform
of NO synthase may play a role in the persistence or even
elevation of NO levels (Licinio et al., 1999; Heneka and Feinstein,
2001). INOS has been shown to be expressed in various brain
regions following injury including the cortex (Olivenza et al.,
2000; Madrigal et al., 2001; Buskila and Amitai, 2010), the
hippocampus (Petrov et al., 2000), and striatum (Lecanu et al.,
1998; Weldon et al., 1998). To our knowledge, no studies have
examined the pattern of iNOS expression in the brain following
acute or chronic NMDA antagonism. Our data indirectly
suggest MK-801 and PCP induces iNOS. However, as discussed
above, AG and EGCG exert multiple iNOS-independent
eﬀects.
Schizophrenia and iNOS Inhibition
It has widely been suggested that the behavioral sequela
associated with NMDA-antagonists may model schizophrenia
more closely than amphetamine-like stimulants. These ﬁndings
are similar to earlier studies of glycine-type NMDA agonists
that also signiﬁcantly reversed motoric, stereotypic, and ataxic
eﬀects of NMDA antagonists (Contreras, 1990). Of interest,
these studies were the basis of successful double-blind studies of
glycine-type NMDA agonists in schizophrenia. iNOS inhibitors
may likewise merit study. Indeed, minocycline is one medication
known to inhibit iNOS and has already been reported to be
beneﬁcial (mainly on negative symptomatology) in many studies
on schizophrenia (Zhang et al., 2007). If minocycline exerts its
eﬀects by an iNOS mechanism, more speciﬁc iNOS inhibitors,
such as AG or 1400W, may be even more therapeutically
eﬃcacious.
Minocycline was studied in schizophrenia based on
preclinical studies similar to our own. For example, one
Frontiers in Pharmacology | www.frontiersin.org 9 December 2015 | Volume 6 | Article 292
Bergstrom et al. iNOS Inhibitors and NMDA Antagonists
study found minocycline pretreatment blocked MK-801
induced hyperlocomotion, prepulse inhibition of startle (PPI)
and striatal/cortical elevations of dopamine as detected by
microdialysis (Zhang et al., 2007). The authors attribute these
ﬁndings to minocycline’s ability to block microglial activation
without speciﬁcally discussing the resulting inhibition of iNOS.
iNOS Inhibitors in the Emergency Room,
Hospital Ward, and in Outpatients
These preliminary results may have clinical relevance for
Emergency room medical staﬀ management of PCP-intoxicated
patients. These patients are among the most dangerous in
psychiatry, because their agitation often culminates in delirium.
Sadly, the response to antipsychotic medications is often
inadequate. iNOS inhibitors merit study in the many dangerous
PCP-intoxicated delirious patients refractory to conventional
antipsychotics.
Phencyclidine-like delirium is often observed in patients
hospitalized for a variety of medical conditions. Most of
these conditions likely elicit suﬃcient inﬂammation to induce
iNOS in the CNS or periphery. Like PCP-intoxicated patients,
such patients are often refractory to high doses of dopamine
antagonists. Future study is warranted to determine whether
PCP-intoxicated patients and patients with PCP-like delirium
beneﬁt from iNOS inhibitors.
Finally, the dissociative medication ketamine is often used
as an anesthetic in an emergency room setting and as a
rapidly acting antidepressant (Abdallah et al., 2015) in depressed
outpatients participating in research studies. Our preclinical
study raises the possibility of iNOS inhibitors preventing aversive
side eﬀects of ketamine-like medications. However, there is an
important caveat. Little is known about how iNOS inhibitors
would interact with the therapeutic eﬀects of ketamine-like
anesthetics and antidepressants.
CONCLUSION
N-methyl-D-aspartate antagonist compounds, despite signiﬁcant
adverse dissociative eﬀects, are widely used in medicine as
anesthetics, rapid-acting antidepressants, and preclinical models
of schizophrenia outcome measures. The results from this
series of experiments provides some of the ﬁrst evidence
that AG and EGCG reduce the psychomotor stimulant and
glutamate-releasing action of NMDA antagonists. Earlier studies
with this behavioral model led to successful clinical trials of
minocycline in the treatment of schizophrenia (Liu et al., 2014).
Dissociative NMDA antagonists may also model dissociative,
dysphoric, and anxiogenic symptoms of PTSD and delirium
in medical patients. Our studies raise the possibility that
other iNOS inhibitors such as AG and EGCG, which share
with minocycline the ability to prevent microglial activation,
may be beneﬁcial in schizophrenia and delirium in medical
patients. Nutraceuticals that counteract inﬂammatory nitric
oxide release (green tea, carob powder and possibly black tea
and chocolate) may also merit consideration as adjuncts to
therapy.
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